Subscribe
Magazine
Videos
Advertise
About Us
Smart Water Summit
Wastewater Summit
Drinking Water
Smart Water
Asset Management
Water Utility Management
Water Reuse
Global Thought Leaders
Podcast
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
WaterWorld Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Mirum Pharmaceuticals, Inc.
< Previous
1
2
3
4
5
Next >
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 08, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference
February 09, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones
January 11, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
January 04, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index
December 15, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in Alagille Syndrome and PFIC2 at NASPGHAN Annual Meeting 2021
December 13, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 2021 Annual Meeting
December 06, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
November 22, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher
November 17, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
November 15, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome
November 15, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021
November 08, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021
November 01, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome
November 01, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older
September 29, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
September 21, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
TAK
Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison
September 13, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 10, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Participate in September Investor Conferences
September 02, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors
August 19, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 10, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
August 05, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021
July 29, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea
July 26, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 12, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Present at Piper Sandler’s Virtual EASL Takeaway Day
June 24, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Presents Analyses From Its Rare Liver Disease Programs at the EASL International Liver Congress 2021
June 23, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Showcase Analyses From Its Rare Liver Disease Programs at The International Liver Congress 2021
June 16, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.